28th September, 2019

BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 51h floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East}, Mumbai - 400 051
Scrip Code: CIPLA EQ

SOCIETE DE LA BOURSE DE
LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir / Madam

Subject: USFDA cGMP inspection completed at Cipla's manufacturing facility in Goa

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Goa manufacturing facility from September 16-27, 2019.

The inspection ended with 12 observations, none of which are related to data integrity. The Company will respond to the agency within the stipulated timeline.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode